Metabolic acidosis is an acid-base disorder characterized by a primary consumption of body buffers including a fall in blood bicarbonate concentration. There are many causes (Table 1) , and there are multiple mechanisms that minimize the fall in arterial pH. A patient with metabolic acidosis may have a normal or even high pH if there is another primary, contravening event that raises the bicarbonate concentration (vomiting) or lowers the arterial PCO 2 (respiratory alkalosis). Metabolic acidosis differs from "acidemia" in that the latter refers solely to a fall in blood pH and not the process.
A recent online survey by Kraut and Kurtz 1 highlighted the uncertainty over when to give bicarbonate to patients with metabolic acidosis. They reported that nephrologists will prescribe therapy at a higher pH compared with critical care physicians. Forty percent of the intensivists would not give bicarbonate unless the pH were Ͻ7.0; only 6% of nephrologists would wait until pH gets this low (P Ͻ 0.01). Also, Ͼ80% of nephrologists would consider the PCO 2 in making their decision to treat, whereas only 59% of intensivists would (P Ͻ 0.02). For patients with lactic acidosis, 86% of nephrologists would treat with bicarbonate, whereas two thirds of intensivists would give bicarbonate (P Ͻ 0.05). A wider variance was noted in the therapy of diabetic ketoacidosis. Sixty percent of nephrologists would treat with bicarbonate versus 28% of intensivists (P Ͻ 0.01). Both groups would administer bicarbonate by constant infusion, targeting an arterial pH of 7.2 as a goal. Seventy-five percent of nephrologists would calculate the amount of bicarbonate required, whereas only one third of intensivists would do this.
Metabolic acidosis results from a loss of bicarbonate from the body (e.g., diarrhea) or from its titration to an anionic base that often can be converted back to bicarbonate, such as seen in diabetic ketoacidosis or lactic acidosis (Table 1) . This nonbicarbonate base anion is commonly termed "potential" bicarbonate. Giving bicarbonate to a patient with a true bicarbonate deficit is not controversial. Controversy arises when the decrease in bicarbonate concentration is the result of its conversion to another base, which, given time, can be converted back to bicarbonate. If one knew that the timely and efficient conversion of acetoacetate and ␤-hydroxybutyrate or lactate back to bicarbonate would occur without morbidity or mortality, then there would be no reason even to contemplate giving bicarbonate.
In considering acute bicarbonate replacement, four questions should be considered: (1) What are the deleterious effects of acidemia, and when are they manifest? (2) When is acidemia severe enough to warrant therapy? (3) How much bicarbonate should be given, and how is that amount calculated? (4) What are the deleterious effects of bicarbonate therapy?
Severe acidemia causes a decrease in myocardial contractility, a fall in cardiac output, and a fall in BP. Acidemia also decreases the binding of norepinephrine to its receptors. It also shifts the oxyhemoglobin curve to the right, allowing more O 2 to be released-the Bohr Effect. Protons bind to intracellular proteins as well as extracellular proteins, especially albumin and hemoglobin. Thus, acidemia may adversely affect cell functions such as enzymatic reactions, ATP generation, fatty acid biosynthesis, and bone formation/resorption. [2] [3] [4] All drugs that are the salts of weak bases or acids have a dissociation constant. Those that are the salts of a weak acid will have more of the drug in the nonionized form in an acid environment and, thus, may manifest increased toxicity. One such example of enhanced toxicity during acidemia is that of acetylsalicylic acid. Other salts of weak acids are tolbutamide, methotrexate, phenobarbital, and phenytoin. The degree of ionization is only one of the factors that determine a drug's solubility across cell membranes, but it is crucial in those body compartments in which pH may change. 5 The optimum extracellular pH for all physiologic mechanisms and organ functions is 7.4. By contrast, intracellular pH is approximately 7.1 in virtually every tissue studied. Many diverse mechanisms are in place to maintain both extracellular and intracellular pH within this very narrow range. Deviations from normal pH will obviously decrease the efficiency of all reactions, although the degree will vary depending on the specific event. For example, whereas acidemia protects the central nervous system against seizures, it sensitizes the myocardium to arrhythmias. Because we do not measure intracellular pH, we must use extracellular pH (arterial or venous) as a surrogate. Most authorities in acid-base physiology would give bicarbonate to a patient with an arterial pH Ͻ7.1, but, as we discuss, this is not a hard and fast rule.
The volume of distribution of bicarbonate is approximately that of total body water. In patients with metabolic acidosis, it is said to vary from 50% to Ͼ100%, depending on the severity of the acidemia. 6 This distribution will obviously affect the calculated bicarbonate deficit. Any calculated amount will be only approximate, of course. The patient should be carefully monitored and bicarbonate administration altered, when given, to suit the course. Fernandez et al. 7 derived a more precise formula for calculating the bicarbonate space: (0.4 ϩ 2.6/ PHCO 3 ) (body weight). A graphic representation of the formula ( Figure 5 in reference 7 ) shows that the "apparent" bicarbonate space increases quite markedly with acidemia but decreases very little with alkalemia. Although they used actual data from several human studies, it is not clear that renal response to acidemia was accounted for as they analyzed acute acid-base disorders. This formula, like any other guide to bicarbonate treatment, should just be a starting point, which is modified as events unfold.
In some patients, only a small amount of bicarbonate may be required. For example, if a patient has a PCO 2 of 13 mmHg and bicarbonate of 4 mEq/L, then his arterial pH is 7.1. If the bicarbonate is doubled (raised to only 8 mEq/ L), then the blood pH will increase to 7.4. This is true only if the PCO 2 does not change. In this example, given a static PCO 2 , if the bicarbonate concentration rises only 1 mEq/L, then the pH would be above 7.2. Arterial PCO 2 typically, however, does not remain the same after NaHCO 3 infusion. In patients with severe acidosis, it rises 6.7 Ϯ 1.8 mmHg when an infusion of sodium bicarbonate is given (1.5 mmol/kg over 5 min). 8 By contrast, infusion with THAM® (Hospira Inc., Lake Forest, IL) or CarbiCarb® (International Medication System, South El Monte, CA) does not affect arterial PCO 2 . 8, 9 These observations have led some investigators to recommend either of these compounds as preferred therapy. 2 Bicarbonate therapy is also associated with an increase in mortality. This has been noted in humans and experimental animals under a variety of acidemic conditions. 10 -12 The increase in mortality is blamed on a fall in BP and cardiac output. There are also shifts in ionized calcium; in strong acid acidosis, potassium also shifts out of the cell sensitizing the heart to abnormal electrical activity and subsequent arrhythmias. Moreover, a "paradoxic" intracellular acidosis may occur when giving bicarbonate therapy because CO 2 generated from its titration freely diffuses across the cell membrane. In addition, both volume expansion and hypernatremia can occur; in patients with compromised cardiac output, fulminate congestive heart failure with flash pulmonary edema may result.
Many in vitro studies show that intracellular alkalinization hastens cell death after anoxia 13 ; if cell water is maintained at pH 6.8, for example, more tissue remains viable. 14, 15 Bicarbonate administration may stimulate superoxide formation, increase proinflammatory cytokine release, or enhance apoptosis. Whether these observations relate to human disorders with acidemia is unknown. Rebound alkalemia may also occur after base administration, especially when the PCO 2 is low. Giving bicarbonate to both animals and humans increases blood lactate and ketone bodies. 6,16 -18 This "potential" bicarbonate will be converted back to actual bicarbonate unless it lost in the urine.
DIABETIC KETOACIDOSIS
In ketoacidosis, substantial amounts of acetoacetate and ␤-hydroxybutyrate are lost in the urine before the patient arrives at the hospital. Thus, not only has the patient converted bicarbonate to "potential bicarbonate," he is truly bicarbonate deficient. More urinary loss of ketone bodies occurs after fluid administration and volume repletion. Hence, the ubiquitous hyperchloremic metabolic acidosis we see the day after insulin therapy is initiated. In ketoacidosis, it is almost never necessary to give bicarbonate even though the patient is bicarbonate deficient unless renal function is permanently impaired. Therapy with fluids and electrolytes restores extracellular volume and renal blood flow, thus enhancing the renal excretion of acid and regenerating bicarbonate. Okuda et al. 18 demonstrated in humans with diabetic ketoacidosis, as well as in the in situ acidemic perfused rat liver (pH of 7.15), that bicarbonate therapy markedly increased blood acetoacetate and ␤-hydroxybutyrate levels. Infusion also increased blood lactate levels approximately threefold. Others have reported similar findings. 19 Indeed, bicarbonate therapy actually delays the removal of ketone bodies from the blood.
LACTIC ACIDOSIS
Lactic acidosis is an ominous event and generally signifies severe tissue hypoxia. It may be secondary to an exogenous toxin such as cyanide or metformin or the result of severe tissue underperfusion from cardiogenic or hemorrhagic shock. The mortality of lactic acidosis approaches 80% or more. This is often because of the inability to correct adequately the underlying disorder(s). A number of studies show even if blood lactate level is lowered with drug therapy, mortality is unchanged. 17, 20, 21 
CASE EXAMPLES
The following two cases demonstrate that therapy for acidemia requires flexibility. 
FINAL THOUGHTS
Bicarbonate therapy for metabolic acidosis is recommended at an arterial pH varying from as low as 6.9 to as high as 7.2. We suggest that bicarbonate therapy be given at pH 7.0 but that this target pH be a guide that is variable depending on clinical setting. Unless efforts are focused on reversing the underlying defects responsible for the acidosis, base therapy will be futile. If bicarbonate is given, then its amount should be calculated as the desired minus the observed bicarbonate concentration using a volume of distribution of total body water. It should also be assumed that the arterial PCO 2 will not change. The desired bicarbonate concentration at this unchanged PCO 2 is that which will give an arterial pH of 7.2. This calculation is only an approximation. At the end of 2 h, an arterial blood gas and chemistries should be remeasured and a new plan for the next 2 h made. Note that patient 1 got no bicarbonate. He was otherwise healthy with a normal cardiovascular system, whereas patient 2 received bicarbonate because he had a severely compromised cardiovascular system. Thus, it is impossible to be dogmatic about the treatment of acidemia. No hard and fast rule works for every patient.
DISCLOSURES
None.
